Keyword

TH-302

Description: TH-302, also called evofosfamide, is a hypoxia-activated prodrug investigated as an anticancer treatment for solid tumors.
Wikidata ID: wiki/Q7670203
OpenAlex ID: keywords/th-302
2018 · Priyamvada Jayaprakash, Midan Ai, et al. · Journal of Clinical Investigation · 433
2019 · Haiyang Guo, Xinpei Ci, et al. · Nature Communications · 264
2008 · Jian-Xin Duan, Hailong Jiao, et al. · Journal of Medicinal Chemistry · 257
2014 · Mitesh J. Borad, Shantan G. Reddy, et al. · Journal of Clinical Oncology · 221
2011 · Fanying Meng, James W. Evans, et al. · Molecular Cancer Therapeutics · 218
2013 · Christopher P. Guise, Alexandra M. Mowday, et al. · 癌症:英文版 · 189
2010 · Jinsong Hu, Damian R. Handisides, et al. · Blood · 159
2016 · Wen-Juan Huang, Wei-Wei Chen, et al. · Oncology Letters · 103
2015 · Francis W. Hunter, Richard J. Young, et al. · Cancer Research · 85
2015 · Juliana Benito, Marc S. Ramirez, et al. · Clinical Cancer Research · 82
2015 · Jonathan W Wojtkowiak, Heather C Cornnell, et al. · Cancer & Metabolism · 82
2013 · Scott Portwood, Deepika Lal, et al. · Clinical Cancer Research · 80
2021 · Yue Li, Long Zhao, et al. · Frontiers in Pharmacology · 75
2016 · Stephanie L. Ham, Ramila Joshi, et al. · Advanced Healthcare Materials · 73
Works count: 263
Citation count: 5,501
Year
Topic
Type